文献速递心境障碍

未用药重性抑郁障碍患者的多巴胺释放:11C-(+)-PHNO PET与fMRI研究

Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.
PubMed 文献 · Biol Psychiatry · 2018-05-25

该研究纳入26例未用药重性抑郁障碍(MDD)患者和26名健康对照,采用11C-(+)-PHNO PET结合右旋安非他命激发评估多巴胺释放能力,并在概率强化任务中行fMRI。

要点

  • MDD组与对照组D2/D3受体可用性(BPND)无显著差异。
  • 多巴胺释放能力与D2/D3可用性均未显著关联奖赏BOLD反应、临床症状或普拉克索疗效。

核心结论

  • 未用药MDD患者腹侧纹状体多巴胺释放能力仅呈趋势性增高,D2/D3受体可用性无差异。
  • 多巴胺释放能力与D2/D3可用性未显著关联奖赏预测误差BOLD反应、抑郁及快感缺失严重度或普拉克索疗效。
  • 作者认为突触前多巴胺失调可能并非MDD的特征,也非多巴胺激动剂治疗应答的前提。

研究设计与样本

  • 研究纳入26例未用药重性抑郁障碍成人患者和26名健康对照。
  • 所有受试者在概率强化任务中接受fMRI,并在口服右旋安非他命前后行11C-(+)-PHNO PET(D3偏好配体)。
  • MDD患者随后接受普拉克索治疗6周。

主要发现

  • MDD组与对照组D2/D3受体可用性(BPND)无差异。
  • 纹状体及纹状体外BPND和ΔBPND百分比与腹侧纹状体奖赏预测误差BOLD反应、抑郁和快感缺失严重度、普拉克索抗抑郁应答均无显著关联。
  • 普拉克索治疗应答率为72.7%。

关键数值与推荐

  • 普拉克索治疗6周应答率为72.7%。

临床怎么用

  • 本研究提示突触前多巴胺失调可能不是MDD的普遍特征,不支持将多巴胺释放能力作为MDD诊断或疗效预测的独立生物标志物。
  • 多巴胺激动剂普拉克索的疗效可能不依赖于突触前多巴胺释放能力或D2/D3受体可用性。

局限性

  • 样本量较小(每组26例),研究仅能检测大效应。
  • 多巴胺释放能力仅在腹侧纹状体呈趋势性差异,未达统计学显著。
  • 研究未发现多巴胺指标与奖赏BOLD反应或临床特征关联,不能排除其他脑区或递质系统的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mesolimbic dopamine system dysfunction is believed to contribute to major depressive disorder (MDD), but molecular neuroimaging of striatal dopamine neurotransmission has yielded mixed results, possibly owing to limited sensitivity of antagonist radioligands used with positron emission tomography to assess dopamine release capacity. This study used an agonist radioligand with agonist challenge to assess dopamine release capacity and D2/D3 receptor availability in MDD. METHODS: Twenty-six treatment-naive adults with MDD and 26 healthy comparison participants underwent functional magnetic resonance imaging during a probabilistic reinforcement task, and positron emission tomography with the D3-preferring ligand [11C]-(+)-PHNO, before and after oral dextroamphetamine. MDD participants then received pramipexole treatment for 6 weeks. RESULTS: MDD participants had trend-level greater dopamine release capacity in the ventral striatum, as measured by percent change in baseline binding potential relative to nondisplaceable compartment (ΔBPND) (-34% vs. -30%; p = .072, d = 0.58) but no difference in D2/D3 receptor availability (BPND). Striatal and extrastriatal BPND and percent change in baseline BPND were not significantly associated with blood oxygen level-dependent response to reward prediction error in the ventral striatum, severity of depression and anhedonia, or antidepressant response to pramipexole (response rate = 72.7%). CONCLUSIONS: [11C]-(+)-PHNO demonstrated high sensitivity to displacement by amphetamine-induced dopamine release, but dopamine release capacity and D2/D3 availability were not associated with ventral striatal activation to reward prediction error or clinical features, in this study powered to detect large effects. While a preponderance of indirect evidence implicates dopaminergic dysfunction in MDD, these findings suggest that presynaptic dopamine dysregulation may not be a feature of MDD or a prerequisite for treatment response to dopamine agonists.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Schneier FR, Slifstein M, Whitton AE, et al. Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. Biol Psychiatry. 2018. PMID: 30041971. doi:10.1016/j.biopsych.2018.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。